The ASX healthcare sector has largely been flat in the last year compared to sectors like tech and financials.
However, broker Bell Potter sees upside in two ASX healthcare shares that have fallen considerably over the last 12 months.
Lets see what the broker had to say about these growth options.
Image source: Getty Images
Anteris Technologies Global Corp (ASX: AVR)
Anteris Technologies is a structural heart company, researches, develops, commercialises, and distributes various medical technologies and devices.
The Company's lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis – a condition where the aortic valve becomes narrowed, restricting blood flow from the heart.
The last year has seen its share price fall almost 70%. At the time of writing this ASX healthcare share is trading at $5.60 a piece.
However, broker Bell Potter sees it as a buy-low option with upside.
The broker has a price target of $15.00, indicating an upside of 167.86%.
The broker's speculative "buy" recommendation is largely based on the potential regulatory approval and commercial manufacturing of the DurAVR valve.
Management has released positive clinical trial updates this year, supporting its ongoing U.S. FDA approval pathway.
Following the recent IPO in the US, the next catalyst is the commencement of a pivotal study which we expect should lead to FDA approval and first commercial revenues in late 2028/2029.
Clarity Pharmaceuticals Ltd (ASX: CU6)
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products.
This ASX healthcare company has also seen its share price fall considerably in the last year.
Its share price is down 45.58% in that span. At the time of writing, shares are trading at $2.77 each.
However, Bell Potter sees upside in this speculative option.
It currently has a price target of $5.20, indicating an upside of 87.73%.
In May, the broker projected optimism in the company thanks to its strong cash position, which gives it enough funding to support key clinical programs until the second half of 2026, without needing to raise more capital right now.
Positive results for two major clinical trials could trigger commercial deals for the company's lead product, which is designed to detect smaller prostate tumours more accurately than current imaging products.
The first regulatory approval is expected by 2027.
